Forte Biosciences, Inc. (FBRX)
| Market Cap | 1.94B +861.0% |
| Revenue (ttm) | n/a |
| Net Income | -87.94M |
| EPS | -4.55 |
| Shares Out | 25.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 76.99 |
| Day's Range | n/a |
| 52-Week Range | 10.11 - 77.20 |
| Beta | 2.64 |
| Analysts | Hold |
| Price Target | 73.80 (-4.14%) |
| Earnings Date | Aug 12, 2026 |
About FBRX
Forte Biosciences, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for autoimmune and autoimmune-related diseases. The company offers products, such as its lead product candidate FB102, a proprietary molecule with applications for celiac disease, vitiligo, and alopecia areata; and services, including the clinical development and management of its Phase 2 clinical trials. Forte Biosciences, Inc. was incorporated in 2007 and is based in Dallas, Texas. As of August 27, 2026, Forte Biosciences, Inc. operates as a subsidiary ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 5 analysts, the average rating for FBRX stock is "Hold." The 12-month stock price target is $73.8, which is a decrease of -4.14% from the latest price.
News
Forte Biosciences Quarterly report: Q2 2026
Forte Biosciences has published its Q2 2026 quarterly earnings report on August 12, 2026.
Halper Sadeh LLC is Investigating Whether FBRX and SAFT are Obtaining Fair Deals for their Shareholders
Insiders may stand to receive substantial financial benefits not available to ordinary shareholders. The proposed transactions may contain terms that could limit superior competing offers.
Forte Biosciences downgraded to Equal Weight from Overweight at Barclays
Barclays downgraded Forte Biosciences (FBRX) to Equal Weight from Overweight with a price target of $77, up from $74, after Argenx (ARGX) agreed to acquire Forte for $77 per share…
After Forte acquisition, H.C. Wainwright says First Tracks could be target
After Argenx (ARGX) announced a deal to acquire Forte (FBRX) for a price of $77 per share, a 43% premium to Friday’s share price and a total equity value of…
Forte Biosciences downgraded to Hold from Buy at Brookline
Brookline downgraded Forte Biosciences (FBRX) to Hold from Buy with a $77 price target after Argenx (ARGX) agreed to acquire Forte for $77 per share in cash. Published first on…
Forte Biosciences downgraded to In Line from Outperform at Evercore ISI
Evercore ISI downgraded Forte Biosciences (FBRX) to In Line from Outperform with a price target of $77, up from $69, after Argenx (ARGX) agreed to acquire Forte for $77 per…
Forte Biosciences downgraded to Hold from Buy at TD Cowen
TD Cowen analyst Yaron Werber downgraded Forte Biosciences (FBRX) to Hold from Buy with a $77 price target after Argenx (ARGX) agreed to acquire Forte for $77 per share in…
M&A News: Forte Biosciences Shares Leap 40% After Argenx Seals $2.2B Immunology Deal
Shares in Forte Biosciences ($FBRX) were 40% healthier in pre-market trading today after it was bought by peer Argenx ($ARGX) for $2.2 billion. Multiple Autoimmune Conditions Dutch immunology innovati...
Argenx to acquire Forte Biosciences for $77 per share in cash
Argenx (ARGX) and Forte (FBRX) announced that the companies have entered into a definitive agreement under which Argenx will acquire Forte Biosciences for $77 per share in cash, representing a…
Argenx to Buy Forte Biosciences for $2.2 Billion
The deal to acquire the Nasdaq-listed Forte represents a 41% premium to its closing price on Friday.
Argenx to buy Forte Biosciences for about $2.2 billion
Belgian-Dutch immunology company argenx will buy Forte Biosciences to add experimental autoimmune drug FB102 to its portfolio, the company said on Monday.
argenx to Acquire Forte Biosciences, Inc., Adding First-in-Class Anti-CD122 Antibody, FB102, to Its Immunology Pipeline
AMSTERDAM & DALLAS--(BUSINESS WIRE)--argenx (Euronext & Nasdaq: ARGX), a global immunology innovation company, and Forte Biosciences, Inc. (Nasdaq: FBRX) today announced that the companies have enter...
Forte Biosciences initiated with an Overweight at Barclays
Barclays initiated coverage of Forte Biosciences (FBRX) with an Overweight rating and $74 price target The firm views the company’s CD122 as a “compelling target across multiple immune disorders” give...
Why Is Forte Biosciences (FBRX) Stock Up Today?
Forte Biosciences stock was up on Friday alongside positive results from a clinical trial.
Forte Biosciences trading resumes
09:42 EDT Forte Biosciences (FBRX) trading resumes
Forte Biosciences trading halted, volatility trading pause
09:32 EDT Forte Biosciences (FBRX) trading halted, volatility trading pause
Forte Biosciences Transcript: Study result
A phase I-B, placebo-controlled trial of FB102 in vitiligo showed robust, statistically significant improvements in facial repigmentation, especially in patients with extensive disease, with effects deepening even after treatment cessation. The dual IL-2/IL-15 blockade mechanism yielded favorable efficacy and safety compared to JAK inhibitors, supporting further development.
Forte Biosciences Slides: Study result
Forte Biosciences has posted slides in relation to its latest quarterly earnings report, which was published on July 9, 2026.
Forte Biosciences Press release: Study result
Forte Biosciences issued a press release on July 9, 2026, disclosing material business information to investors.
Forte Biosciences’ FB102 shows efficacy in vitiligo Phase 1b study
Forte Biosciences (FBRX) announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved 29.6% mean FVASI improvement from baseline at week 24; res...
FB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment Period
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...
Forte Biosciences Registration statement: Registration filing
Forte Biosciences filed a registration statement on June 8, 2026, providing details about a securities offering with the SEC.
Forte Biosciences Registration statement: Registration filing
Forte Biosciences filed a registration statement on June 2, 2026, providing details about a securities offering with the SEC.
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...
Forte Biosciences, Inc. Announces First Quarter 2026 Results and Provides Update
DALLAS--(BUSINESS WIRE)--Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced ...